WO2010131922A4 - Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant - Google Patents

Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant Download PDF

Info

Publication number
WO2010131922A4
WO2010131922A4 PCT/KR2010/003060 KR2010003060W WO2010131922A4 WO 2010131922 A4 WO2010131922 A4 WO 2010131922A4 KR 2010003060 W KR2010003060 W KR 2010003060W WO 2010131922 A4 WO2010131922 A4 WO 2010131922A4
Authority
WO
WIPO (PCT)
Prior art keywords
benzamide
aminophenyl
methyl
oxo
oxoisoindolin
Prior art date
Application number
PCT/KR2010/003060
Other languages
English (en)
Other versions
WO2010131922A3 (fr
WO2010131922A2 (fr
Inventor
Jung Nyoung Heo
Bum Tae Kim
Hyuk Lee
Sung Youn Chang
Zang Hee Lee
Seong Hwan Kim
Hyun-Mo Ryoo
Original Assignee
Korea Research Institute Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090042585A external-priority patent/KR20100123379A/ko
Priority claimed from KR1020090042691A external-priority patent/KR101142053B1/ko
Application filed by Korea Research Institute Of Chemical Technology filed Critical Korea Research Institute Of Chemical Technology
Priority to JP2012510756A priority Critical patent/JP5713999B2/ja
Priority to EP10775124A priority patent/EP2429987A4/fr
Priority to US13/320,117 priority patent/US8716326B2/en
Publication of WO2010131922A2 publication Critical patent/WO2010131922A2/fr
Publication of WO2010131922A3 publication Critical patent/WO2010131922A3/fr
Publication of WO2010131922A4 publication Critical patent/WO2010131922A4/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur un composé amide ou un sel pharmaceutiquement acceptable de celui-ci, sur un procédé de préparation de celui-ci, et sur une composition pharmaceutique le comprenant. Le composé amide de l'invention facilite la formation osseuse et inhibe la perte osseuse, et est par conséquent utile pour prévenir et traiter des troubles osseux tels que l'ostéoporose, l'ostéodystrophie, une fracture osseuse, une maladie périodontique, la maladie de Paget, une métastase osseuse et une polyarthrite rhumatoïde.
PCT/KR2010/003060 2009-05-15 2010-05-14 Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant WO2010131922A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012510756A JP5713999B2 (ja) 2009-05-15 2010-05-14 アミド化合物、その製造方法及びそれを含む薬学組成物
EP10775124A EP2429987A4 (fr) 2009-05-15 2010-05-14 Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant
US13/320,117 US8716326B2 (en) 2009-05-15 2010-05-14 Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2009-0042585 2009-05-15
KR10-2009-0042691 2009-05-15
KR1020090042585A KR20100123379A (ko) 2009-05-15 2009-05-15 벤즈아마이드 유도체, 이의 제조방법 및 이를 포함하는 골 질환의 예방 및 치료용 약학 조성물
KR1020090042691A KR101142053B1 (ko) 2009-05-15 2009-05-15 이소인돌리논 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물

Publications (3)

Publication Number Publication Date
WO2010131922A2 WO2010131922A2 (fr) 2010-11-18
WO2010131922A3 WO2010131922A3 (fr) 2011-03-24
WO2010131922A4 true WO2010131922A4 (fr) 2011-05-26

Family

ID=43085472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003060 WO2010131922A2 (fr) 2009-05-15 2010-05-14 Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant

Country Status (4)

Country Link
US (1) US8716326B2 (fr)
EP (1) EP2429987A4 (fr)
JP (1) JP5713999B2 (fr)
WO (1) WO2010131922A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330894B8 (fr) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
EP2526093B1 (fr) * 2010-01-22 2016-08-17 Acetylon Pharmaceuticals, Inc. Composés amide inverse en tant qu'inhibiteurs de protéine désacétylase et procédés d'utilisation associés
CA2828524C (fr) 2011-02-28 2020-01-07 Repligen Corporation Inhibiteurs de l'histone deacetylase
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102850236B (zh) * 2011-06-27 2016-05-18 国药一心制药有限公司 新型苯甲酰胺类组蛋白去乙酰化酶抑制剂及其应用
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
JP6503338B2 (ja) 2013-03-15 2019-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤
EP2801569A1 (fr) * 2013-05-09 2014-11-12 Ikerchem, S.L. Inhibiteurs des histone-désacétylases à base de dérivés de polyhydroacridine tricycliques et analogues et possédant des anneaux à cinq et sept chaînons saturé fusionnés
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
CA2932411A1 (fr) 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinaisons d'inhibiteurs d'histone desacetylase et medicaments immunomodulateurs
CN107205988A (zh) 2014-07-07 2017-09-26 埃斯泰隆制药公司 利用组蛋白脱乙酰酶抑制剂治疗白血病
CA2969790A1 (fr) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinaisons d'inhibiteurs d'histone deacetylase et de bendamustine
AR105812A1 (es) 2015-06-08 2017-11-15 Acetylon Pharmaceuticals Inc Métodos para la preparación de inhibidores de proteína deacetilasa
WO2016200919A1 (fr) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Formes cristallines d'un inhibiteur de l'histone désacétylase
CA3001799A1 (fr) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Composes benzolactames utilises en tant qu'inhibiteurs de proteine kinase
JP2019515909A (ja) 2016-04-19 2019-06-13 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
KR100194535B1 (ko) * 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
KR100194534B1 (ko) * 1996-06-29 1999-06-15 우종일 2-클로로-3,5-비스 (트피플루오르메틸) 페닐 벤조일 우레아 유도체 및 이의 제조방법
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE60138658D1 (de) * 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
WO2002074298A1 (fr) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
AU2003292888A1 (en) * 2002-12-27 2004-07-22 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
JP4939941B2 (ja) * 2003-08-26 2012-05-30 株式會社アモーレパシフィック ヒドロキサム酸誘導体及びその製造方法
WO2006065075A1 (fr) * 2004-12-14 2006-06-22 Biorunx Co. Ltd. Procede d'accroissement de l'activite de formation osseuse de la bmp par acetylation de la runx2
WO2007144341A1 (fr) * 2006-06-12 2007-12-21 Vrije Universiteit Brussel Différentiation de cellules
US8389553B2 (en) * 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2330894B8 (fr) * 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac

Also Published As

Publication number Publication date
WO2010131922A3 (fr) 2011-03-24
US8716326B2 (en) 2014-05-06
US20120065396A1 (en) 2012-03-15
EP2429987A4 (fr) 2012-10-03
EP2429987A2 (fr) 2012-03-21
WO2010131922A2 (fr) 2010-11-18
JP5713999B2 (ja) 2015-05-07
JP2012526803A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2010131922A4 (fr) Composé amide, procédé de préparation de celui-ci et composition pharmaceutique le comprenant
JP2012526803A5 (fr)
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
JP2007519754A5 (fr)
JP2017533968A5 (fr)
AU2015335694A1 (en) Indole carboxamide compounds useful as kinase inhibitors
HUP0103987A2 (en) Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
RU2007147955A (ru) Способ получения дигидрохиназолинов
ATE496043T1 (de) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
WO2012039371A1 (fr) Composé de cyclopropane
JP2016528201A5 (fr)
CA2797622A1 (fr) Composes de 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine ou de 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine
JP2009504792A5 (fr)
JP2004203748A (ja) 新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
RS54415B1 (en) BENZAMIDE SUBSTITUTED DERIVATIVES
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
PE20091243A1 (es) Compuesto heterociclico fusionado
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
RU2013130925A (ru) Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности
CA2444489A1 (fr) Composes de benzimidazolone
JP2012527487A5 (fr)
RU2007123251A (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
CA2444108A1 (fr) Analogues de la nociceptine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10775124

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13320117

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012510756

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010775124

Country of ref document: EP